One large drop for MannKind as Afrezza stretches time and money
This article was originally published in Scrip
Executive Summary
MannKind informed investors and analysts on 10 May that there may be even more delays in its resubmission of its application for its inhaled recombinant insulin, Afrezza – as it makes its third attempt to gain FDA regulatory approval.